Patents Examined by Michelle Horning
-
Patent number: 7993879Abstract: Fluorescent indicators including a binding protein moiety, a donor fluorescent protein moiety, and an acceptor fluorescent protein moiety are described. The binding protein moiety has an analyte-binding region which binds an analyte and causes the indicator to change conformation upon exposure to the analyte. The donor moiety and the acceptor moiety change position relative to each other when the analyte binds to the analyte-binding region. The donor moiety and the acceptor moiety exhibit fluorescence resonance energy transfer when the donor moiety is excited and the distance between the donor moiety and the acceptor moiety is small. The indicators can be used to measure analyte concentrations in samples, such as calcium ion concentrations in cells.Type: GrantFiled: January 17, 2006Date of Patent: August 9, 2011Assignee: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, Atsushi Miyawaki
-
Patent number: 7951786Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.Type: GrantFiled: November 28, 2008Date of Patent: May 31, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Dennis Klinman, Rainald Zeuner, Daniela Verthelyi, Ihsan Gursel, Mayda Gursel
-
Patent number: 7943148Abstract: Highly immunoreactive viral peptides are disclosed which are derived from the E protein of major groups of the Flavivirus genus by computational analyses. These peptides are used in reliable diagnostic methods for the detection and diagnosis of Flavivirus, detecting the presence of antibodies against Flavivirus, and to form vaccine composition(s) for the prevention of Flavivirus infections in humans.Type: GrantFiled: April 2, 2008Date of Patent: May 17, 2011Assignee: The United States of America as Represented by the Secretary of the ArmyInventors: Jose-Luis Sagripanti, Raja Mazumder, Cathy Huey-Hwa Wu
-
Patent number: 7939269Abstract: The present invention relates to a method for diagnosing cancer and a detection reagent based on detection of Epstein-Barr virus nuclear antigen 2 (EBNA2) coactivator p100 contained in a specimen, and a method for treating cancer by controlling expression of EBNA2 coactivator p100 protein or a gene thereof.Type: GrantFiled: September 17, 2007Date of Patent: May 10, 2011Assignee: Tosoh CorporationInventors: Shin Egawa, Hidetoshi Kuruma, Hiroyuki Takahashi, Koji Igarashi
-
Patent number: 7932367Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.Type: GrantFiled: October 27, 2003Date of Patent: April 26, 2011Assignee: Idera Pharmaceuticals, Inc.Inventors: Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
-
Patent number: 7932043Abstract: Methods of preparing monoclonal antibodies that differentially bind to a single conformer of a protein of interest are described. Passive immunization using these antibodies as well as use of conformer-specific antibodies as diagnostic reagents for the purpose of stratification of patient populations with regards to disease outcome, drug efficacy or drug sensitivity is also disclosed as well as active immunization with the protein conformer. In the screening techniques, detection can be for example by tissue immunostaining, western blotting or solution IP. A specific mab termed 7VC which shows conformation specificity to CtmPrP, a prion protein conformer that triggers neurodegeneration under specific assay conditions of pH and copper concentration, is described. A second specific antibody termed 19B10 shows conformation specificity for NtmPrP, a prion protein conformer that downregulates total PrP expression and effects cell differentiation.Type: GrantFiled: August 18, 2003Date of Patent: April 26, 2011Assignee: The University of California at San FranciscoInventors: Carsten Korth, Vishwanath R. Lingappa
-
Patent number: 7928193Abstract: The present invention features antigen binding protein that bind to a SR-BI target region identified herein as a region involved in HCV E2 binding. Identified target regions are regions bound by a single-chain antibody of SEQ ID NOs: 1, 2, 3 or 4.Type: GrantFiled: July 1, 2005Date of Patent: April 19, 2011Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.Inventors: Riccardo Cortese, Alessandra Luzzago, Alfredo Nicosia, Alessandra Vitelli
-
Patent number: 7910366Abstract: The invention relates to a cell strain induced from MDCK cells as dog kidney-derived cells, and being able to be cultured without ingredients derived from animals. The cell strain is produced by adapting a MDCK cell to a medium without a serum but with a cell growth factor; and culturing the cell in a medium with an RPMI 1640 medium and a soybean-derived peptone but without ingredients derived from animals.Type: GrantFiled: March 10, 2005Date of Patent: March 22, 2011Assignee: Kyoritsu Seiyaku CorporationInventor: Masami Mochizuki
-
Patent number: 7910113Abstract: Described herein is the development of fusion proteins useful for inducing tolerance in a subject. In particular embodiments, the tolerizing agents are useful for influence autoimmune, inflammatory, and/or allergic reactions. Example tolerizing fusion proteins contain a targeting portion (which delivers the fusion protein) and a toleragen or allergen or other antigen to which tolerance is desired in a subject. In particular examples, it is demonstrated that a p?1 fusion protein, when administered orally, facilitates systemic and mucosal tolerance. Also described is the nasal delivery of fusion proteins, for instance for restoring immunogenicity.Type: GrantFiled: March 27, 2007Date of Patent: March 22, 2011Assignees: Montana State University, UAB Research FoundationInventors: David W. Pascual, Kohtaro Fujihashi, Massimo Maddaloni
-
Patent number: 7863006Abstract: This application includes description of antibodies for specifically detecting prions of human origin and methods for detecting pathogenic prions. In some embodiments, the antibodies bind to an epitope characteristic of a human prion protein which is not found in the prion proteins of other species. In some embodiments, the antibodies are not cross-reactive with cow, Syrian Gold hamster, mouse, or rat prions. The application also includes a conformation-dependent immunoassay method for detecting pathogenic prions in a sample containing a prion (PrP) protein. The PrP protein may be present in a first conformation and a second conformation, such as PrPc and PrPSc in which the two conformations have different binding affinity for the antibody used to detect them.Type: GrantFiled: February 27, 2007Date of Patent: January 4, 2011Assignee: CSL Behring GmbHInventors: Martin Vey, Wiegang Lang, Albrecht Groener, Anne Bellon
-
Patent number: 7863008Abstract: The present invention relates to recombinant expression vectors which express segments of deoxyribonucleic acid that encode recombinant HIV and HCV antigens. These recombinant expression vectors are transformed into host cells and used in a method to express large quantities of these antigens. The invention also provides compositions containing certain of the isolated antigens, diagnostic systems containing these antigens and methods of assaying body fluids to detect the presence of antibodies against the antigens of the invention.Type: GrantFiled: March 14, 2008Date of Patent: January 4, 2011Assignees: Bioprocess Pty Ltd., P. Hoffmann-La Roche, Ltd.Inventors: Suzanne Zebedee, Genevieve Inchauspe, Marc S. Nasoff, Alfred M Prince
-
Patent number: 7854928Abstract: A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus. In one embodiment, the therapeutically effective dose is from about 103 pfus to about 1012 pfus and is delivered by direct injection into a group of cancer cells or via intravenous injection.Type: GrantFiled: January 15, 2010Date of Patent: December 21, 2010Assignee: Mayo Foundation for Medical Education and ResearchInventors: Stephen J. Russell, Adele Kay Fielding, Kah-Whye Peng, Deanna Grote
-
Patent number: 7846677Abstract: Peptides comprising an Rpt1 domain of an INI1/hSNF5 which inhibit HIV-1 production in a human cell, and vectors encoding those peptides are provided. Also provided are methods of inhibiting HIV-1 production in a cell, or spread of the HIV-1 to another cell, by treating the cells with the above peptides or vectors. Other methods of inhibiting HIV-1 production in a cell, or spread of the HIV-1 to another cell, by inhibiting production of INI1/hSNF5 are provided. Additionally, methods of determining whether a test compound inhibits HIV-1 virion production in a mammalian cell, or spread of the HIV-1 to another cell, are provided. Those methods comprise determining whether the test compound inhibits the production of INI1/hSNF5 or disrupts the interaction of HIV-1 integrase with INI1/hSNF5.Type: GrantFiled: December 18, 2007Date of Patent: December 7, 2010Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Ganjam V. Kalpana
-
Patent number: 7838002Abstract: The present invention relates to a novel form of core+1 protein of Hepatitis C virus (HCV), designated shorter form core+1 protein. The shorter form core+1 protein of Hepatitis C virus is the product of translation of a coding sequence consisting of all or part of a nucleotide sequence extending from nucleotide 598 to nucleotide 920 within the core+1 ORF of HCV represented on FIG. 3B. The invention also provides methods for detecting infection by Hepatitis C virus in biological samples, methods of screening compounds which interact with viral propagation in HCV infected cells or screening of compounds impaction on the expression of shorter form core+1 protein and uses of these compounds for the preparation of compositions useful for their anti-viral activities.Type: GrantFiled: January 3, 2006Date of Patent: November 23, 2010Assignees: Institut Pasteur, Institut Pasteur HelleniqueInventors: Penelope Mavromara, Niki Vassilaki
-
Patent number: 7807386Abstract: The aim of the present invention is to provide a non-intrusive way to isolate, concentrate and monitor the TSE disease-related pathogenic prion protein. The invention described several peptides and their ability to capture PrPSc from brain homogenate of prion disease infected animal and human. These eight peptides do not capture cellular prion protein from individual with no prion disease.Type: GrantFiled: January 22, 2009Date of Patent: October 5, 2010Assignee: Ortho-Clinical Diagnostics, Inc.Inventor: Jian Zheng
-
Patent number: 7807801Abstract: A method of inhibiting replication of a flavivirus in animal cells, and an oligonucleotide compound for use in the method are disclosed. The oligonucleotide analog (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the cells, (iii) contains between 8-40 nucleotide bases, and (iv) has a sequence of at least 8 bases complementary to a region of the virus' positive strand RNA genome that includes at least a portion of SEQ ID NOS:1-4. Exposure of cells infected with a flavivirus to the analog is effective to form within the cells, a heteroduplex structure composed of the virus ssRNA and the oligonucleotide, characterized by a Tm of dissociation of at least 45° C., and having disrupted base pairing between the virus' 5? and 3? cyclization sequences.Type: GrantFiled: August 5, 2004Date of Patent: October 5, 2010Assignee: AVI BioPharma Inc.Inventors: Patrick L. Iversen, David A. Stein
-
Patent number: 7794976Abstract: Recombinant expression vectors are provided comprising a 3?UTR of a light chain and an Epstein-Barr virus origin of replication. Also provided are host cells comprising such vectors and methods of producing recombinant protein with such vectors. Additional methods of producing a recombinant protein involve contacting cells with a first and second vector, each of which encode a different polypeptide chain, and wherein the second vector is present in an amount which is about 1.5 to 2.5 times as much as that of the first vector. Cells also can be transfected with a recombinant transient expression vector encoding a protein and are cultured in a medium in a membrane-enhanced culturing vessel to produce recombinant protein.Type: GrantFiled: July 31, 2007Date of Patent: September 14, 2010Assignee: XOMA Technology Ltd.Inventors: Masahisa Handa, Arnold H. Horwitz, Robyn Cotter, Eddie Batista
-
Patent number: 7790181Abstract: Live attenuated Eastern Equine Encephalitis (EEE) vaccines that outperform the PE-6 vaccine in mice aerosol challenged with >1,000×LD50. Candidates include four furin-cleavage deletion mutants and one E3 deletion mutant. Each vaccine provided protection in birds against antigenically distinct North and South American strains of EEE. The PE-6 vaccine does not provide protection against South American EEEs. Animals inoculated with each of the vaccines of the invention developed neutralizing antibodies to EEE.Type: GrantFiled: May 26, 2004Date of Patent: September 7, 2010Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Peter L. Platteborze, Michael D. Parker
-
Patent number: 7785595Abstract: The present invention provides liquid formulations of antibodies or fragments thereof that specifically bind to a hepatitis B virus (HBV) antigen, which formulations exhibit stability, low to undetectable levels of aggregations, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with HBV infection utilizing the liquid formulations of the present invention.Type: GrantFiled: April 18, 2005Date of Patent: August 31, 2010Assignee: Yeda Research and Development Company LimitedInventors: Shlomo Dagan, Rachel Eren, Hemant Kumar Misra, Walter G. Gowan, Jr., Sandra O'Connor
-
Patent number: 7744900Abstract: Expression cassettes are provided comprising a promoter operably linked to a nucleic acid molecule which, when transcribed in vivo, forms double-stranded RNA that induces the production of interferon. Expression cassettes also are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, forms a ribozyme or antisense RNA molecule that stimulates an immune response. In addition, expression cassettes are provided comprising a promoter operably linked to a ribozyme or antisense nucleic acid molecule which, when transcribed in vivo, stimulates apoptosis. Finally, gene delivery vectors are provided which contain such expression cassettes, host cells containing the gene delivery vectors, and methods of utilizing the expression cassettes, gene delivery vectors, and host cells.Type: GrantFiled: April 29, 2008Date of Patent: June 29, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Thomas W Dubensky, Jr., John M Polo, Barbara A Belli, Silvia Perri, Timothy C Fong